HLS Therapeutics Inc.
HLS.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 56.42M | 56.77M | 56.62M | 56.94M | 58.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.42M | 56.77M | 56.62M | 56.94M | 58.89M |
| Cost of Revenue | 15.60M | 15.46M | 14.66M | 14.36M | 14.23M |
| Gross Profit | 40.82M | 41.31M | 41.96M | 42.59M | 44.67M |
| SG&A Expenses | 24.20M | 25.57M | 26.93M | 26.75M | 27.30M |
| Depreciation & Amortization | 21.79M | 22.16M | 22.72M | 24.33M | 27.03M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.58M | 63.18M | 64.31M | 65.43M | 68.55M |
| Operating Income | -5.16M | -6.41M | -7.69M | -8.49M | -9.66M |
| Income Before Tax | -14.80M | -13.91M | -15.58M | -17.97M | -20.39M |
| Income Tax Expenses | 245.00K | 4.08M | 4.07M | 4.06M | 3.70M |
| Earnings from Continuing Operations | -15.04 | -17.99 | -19.66 | -22.03 | -24.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.04M | -17.99M | -19.66M | -22.03M | -24.09M |
| EBIT | -5.16M | -6.41M | -7.69M | -8.49M | -9.66M |
| EBITDA | 16.58M | 15.70M | 14.99M | 15.77M | 17.30M |
| EPS Basic | -0.57 | -0.67 | -0.72 | -0.69 | -0.75 |
| Normalized Basic EPS | -0.35 | -0.40 | -0.43 | -0.41 | -0.42 |
| EPS Diluted | -0.59 | -0.68 | -0.73 | -0.70 | -0.76 |
| Normalized Diluted EPS | -0.35 | -0.40 | -0.43 | -0.41 | -0.42 |
| Average Basic Shares Outstanding | 125.46M | 125.53M | 125.68M | 127.22M | 127.68M |
| Average Diluted Shares Outstanding | 125.46M | 125.53M | 125.68M | 127.22M | 127.68M |
| Dividend Per Share | -- | -- | -- | 0.00 | 0.00 |
| Payout Ratio | -- | -- | -- | 0.00% | 0.00% |